As of January 1, 2025, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will update its Tocilizumab utilization criteria to prefer Tyenne®. Actemra® will be removed from preferred status.
To ensure a smooth transition, patients with a current Actemra prior authorization approval may transition to the preferred product (Tyenne) on January 1, 2025, without requirement of an additional prior authorization at that time. Initial Tyenne prior authorizations will be active through the original Actemra prior authorization approval date. An additional prior authorization will be required after January 1, 2025, to continue Actemra therapy.
Requests for continuation of Actemra will not be able to be reviewed until after January 1, 2025. Please submit all requests through Blue e for fastest processing times.
Learn more about Tocilizumab (Actemra®) and Tocilizumab Biosimilars.
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.